Search results
4 wrz 2023 · When considering agents that may simultaneously improve upon sleep quality and enhance cognition, the wake-promoting agent, modafinil, is an ideal candidate. It is FDA-approved for improving wakefulness in adults with excessive daytime sleepiness due to primary sleep disorders (Provigil ®, 2007).
3 gru 2013 · Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea. Existing trials of modafinil for fatigue and EDS associated with neurological disorders provided inconsistent results.
When prescribed for MS-related fatigue management, modafinil works by promoting wakefulness and increasing alertness without causing drowsiness or disrupting nighttime sleep. People with multiple sclerosis often report increased energy levels, reduced feelings of tiredness, improved cognitive function, and an overall improvement in their ...
10 maj 2023 · Modafinil (Provigil) helps to keep people awake. First approved by the FDA in 1998 to treat narcolepsy, modafinil is also used to treat excessive daytime sleepiness caused by obstructive sleep apnea (OSA) or shift work sleep disorder (SWSD).
6 lut 2009 · Modafinil, an orally administered wake-promoting agent, is indicated to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD), and narcolepsy (PROVIGIL ® 2007).
1 maj 2002 · Modafinil is a unique and relatively benign CNS stimulant that can effectively promote wakefulness in patients with excessive daytime somnolence. Modafinil has been attracting attention recently in the sleep-medicine field because its properties include the ability to promote wakefulness.
28 cze 2022 · Modafinil is a eugeroic agent approved for treating fatigue in narcolepsy and shift-work sleep disorder. It has been shown to have antioxidant effects preclinically and clinical efficacy in treating neurocognitive symptoms.
